西地那非治疗射血分数保留心衰:RELAX试验靶向代谢组学分析
RELAX试验中,西地那非对HFpEF患者运动能力和临床状态无影响;本研究对160例患者基线和24周血浆样本进行代谢组学分析,发现西地那非组7种代谢物变化而安慰剂组无变化,短链二羧基酰基肉碱和天冬酰胺/天冬氨酸与临床结局相关。
要点
- 西地那非组7种代谢物变化,安慰剂组无变化,涉及氨基酸和酰基肉碱。
- 长链和短链二羧基酰基肉碱增加分别与内皮素-1和肌酐/胱抑素C升高相关。
- 基线短链二羧基酰基肉碱和天冬酰胺/天冬氨酸较高与更差临床排名评分相关。
核心结论
- 西地那非可能通过影响线粒体功能或内质网应激等机制,与RELAX试验的中性结果相关。
- 短链二羧基酰基肉碱代谢物和天冬酰胺/天冬氨酸可能作为HFpEF不良临床结局的生物标志物。
研究设计与样本
- RELAX临床试验中160例稳定门诊HFpEF患者的配对基线和24周血浆样本分析。
- 采用流动注射串联质谱检测60种代谢物和常规方法检测5种代谢物。
- 西地那非组79例,安慰剂组81例;口服20 mg每日三次12周,随后60 mg每日三次12周。
主要发现
- 长链酰基肉碱和短链二羧基酰基肉碱的增加分别与内皮素-1和肌酐/胱抑素C的增加相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Phosphodiesterase-5 inhibition with sildenafil compared with a placebo had no effect on the exercise capacity or clinical status of patients with heart failure with preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure with Preserved Ejection Fraction (RELAX) clinical trial. Metabolic impairments may explain the neutral results. OBJECTIVE: To test the hypothesis that profiling metabolites in the RELAX trial would clarify the mechanisms of sildenafil effects and identify metabolites associated with clinical outcomes in HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Paired baseline and 24-week plasma samples of 160 stable outpatient individuals with HFpEF enrolled in the RELAX clinical trial were analyzed using flow injection tandem mass spectrometry (60 metabolites) and conventional assays (5 metabolites). INTERVENTIONS: Sildenafil (n = 79) or a placebo (n = 81) administered orally at 20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary measure was metabolite level changes between baseline and 24 weeks stratified by treatments. Secondary measures included correlations between metabolite level changes and clinical biomarkers and associations between baseline metabolite levels and the composite clinical score. RESULTS: No metabolites changed between baseline and 24 weeks in the group treated with a placebo; however, 7 metabolites changed in the group treated with sildenafil, including decreased amino acids (alanine and proline; median change [25th-75th], -38.26 [-100.3 to 28.19] and -28.24 [-56.29 to 12.08], respectively; false discovery rate-adjusted P = .01 and .03, respectively), and increased short-chain dicarboxylacylcarnitines glutaryl carnitine, octenedioyl carnitine, and adipoyl carnitine (median change, 6.19 [-3.37 to 14.18], 2.72 [-3 to 12.57], and 10.72 [-11.23 to 29.57], respectively; false discovery rate-adjusted P = .01, .04, and .05, respectively), and 1 long-chain acylcarnitine metabolite (palmitoyl carnitine; median change, 7.83 [-5.64 to 26.99]; false discovery rate-adjusted P = .03). The increases in long-chain acylarnitine metabolites and short-chain dicarboxylacylcarnitines correlated with increases in endothelin-1 and creatinine/cystatin C, respectively. Higher baseline levels of short-chain dicarboxylacylcarnitine metabolite 3-hydroxyisovalerylcarnitine/malonylcarnitine and asparagine/aspartic acid were associated with worse clinical rank scores in both treatment groups (β, -96.60, P = .001 and β, -0.02, P = .01; after renal adjustment, P = .09 and .02, respectively). CONCLUSIONS AND RELEVANCE: Our study provides a potential mechanism for the effects of sildenafil that, through adverse effects on mitochondrial function and endoplasmic reticulum stress, could have contributed to the neutral trial results in RELAX. Short-chain dicarboxylacylcarnitine metabolites and asparagine/aspartic acid could serve as biomarkers associated with adverse clinical outcomes in HFpEF.
引用
- Wang H, Anstrom K, Ilkayeva O, et al. Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. JAMA Cardiol. 2017. PMID: 28492915. doi:10.1001/jamacardio.2017.1239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。